JP2019519770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519770A5 JP2019519770A5 JP2018562324A JP2018562324A JP2019519770A5 JP 2019519770 A5 JP2019519770 A5 JP 2019519770A5 JP 2018562324 A JP2018562324 A JP 2018562324A JP 2018562324 A JP2018562324 A JP 2018562324A JP 2019519770 A5 JP2019519770 A5 JP 2019519770A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- biomarker
- sequence
- peripheral
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 20
- 239000000090 biomarker Substances 0.000 claims 9
- 210000000822 natural killer cell Anatomy 0.000 claims 9
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 8
- 230000002093 peripheral effect Effects 0.000 claims 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022072884A JP7511806B2 (ja) | 2016-05-30 | 2022-04-27 | 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171885.3 | 2016-05-30 | ||
| EP16171885 | 2016-05-30 | ||
| PCT/EP2017/063045 WO2017207574A1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022072884A Division JP7511806B2 (ja) | 2016-05-30 | 2022-04-27 | 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519770A JP2019519770A (ja) | 2019-07-11 |
| JP2019519770A5 true JP2019519770A5 (OSRAM) | 2020-07-16 |
| JP7066639B2 JP7066639B2 (ja) | 2022-05-13 |
Family
ID=56116221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562324A Active JP7066639B2 (ja) | 2016-05-30 | 2017-05-30 | 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 |
| JP2022072884A Active JP7511806B2 (ja) | 2016-05-30 | 2022-04-27 | 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022072884A Active JP7511806B2 (ja) | 2016-05-30 | 2022-04-27 | 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20190195879A1 (OSRAM) |
| EP (2) | EP3465214B1 (OSRAM) |
| JP (2) | JP7066639B2 (OSRAM) |
| KR (1) | KR102416144B1 (OSRAM) |
| CN (2) | CN109313194B (OSRAM) |
| AU (1) | AU2017272608B2 (OSRAM) |
| BR (1) | BR112018074603A2 (OSRAM) |
| CY (1) | CY1124768T1 (OSRAM) |
| DK (2) | DK3916392T3 (OSRAM) |
| EA (1) | EA201892542A1 (OSRAM) |
| ES (2) | ES2981046T3 (OSRAM) |
| FI (1) | FI3916392T3 (OSRAM) |
| HR (2) | HRP20210938T1 (OSRAM) |
| HU (2) | HUE054860T2 (OSRAM) |
| IL (1) | IL263103B2 (OSRAM) |
| LT (2) | LT3465214T (OSRAM) |
| MA (2) | MA57021B1 (OSRAM) |
| MD (2) | MD3465214T2 (OSRAM) |
| MX (2) | MX388502B (OSRAM) |
| PL (2) | PL3465214T3 (OSRAM) |
| PT (2) | PT3916392T (OSRAM) |
| RS (2) | RS65540B1 (OSRAM) |
| SG (2) | SG10201911958SA (OSRAM) |
| SI (2) | SI3916392T1 (OSRAM) |
| SM (2) | SMT202100291T1 (OSRAM) |
| WO (1) | WO2017207574A1 (OSRAM) |
| ZA (2) | ZA201808647B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3954388A1 (en) | 2015-08-21 | 2022-02-16 | MorphoSys AG | Combinations and uses thereof |
| IL320372A (en) | 2016-10-28 | 2025-06-01 | Morphosys Ag | Combination of anti-CD19 antibody with BCL-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| SG11202111343TA (en) * | 2019-05-03 | 2021-11-29 | Morphosys Ag | Anti-cd19 therapy in patients having a limited number of nk cells |
| PH12022551008A1 (en) * | 2019-10-31 | 2023-03-20 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| KR20220104176A (ko) * | 2019-10-31 | 2022-07-26 | 모르포시스 아게 | 순차적 항-cd19 요법 |
| CA3204063A1 (en) * | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69939939D1 (de) * | 1998-08-11 | 2009-01-02 | Idec Pharma Corp | Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern |
| ATE450529T1 (de) | 2001-02-27 | 2009-12-15 | Governement Of The United Stat | Analoga von thalidomid als angiogeneseinhibitoren |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| KR101289537B1 (ko) * | 2005-02-15 | 2013-07-31 | 듀크 유니버시티 | 항-ｃｄ19 항체 및 종양학에서 이의 용도 |
| KR20080032097A (ko) | 2005-06-20 | 2008-04-14 | 메다렉스, 인코포레이티드 | 씨디19 항체 및 그의 용도 |
| DK2270050T3 (da) | 2005-12-30 | 2013-08-12 | Merck Patent Gmbh | Anti-CD19-antistoffer med nedsat immunogenicitet |
| HRP20140331T1 (hr) | 2006-08-14 | 2014-05-09 | Xencor, Inc. | Optimizirana antitijela usmjerena na cd19 |
| MX2009002414A (es) | 2006-09-08 | 2009-05-20 | Medimmune Llc | Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria. |
| EP2062047B1 (fr) | 2006-09-13 | 2011-03-09 | Glycode | Methode d'investigation de la reponse a un traitement par un anticorps monoclonal |
| EP3392273A1 (en) | 2007-05-30 | 2018-10-24 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| PT2211904T (pt) | 2007-10-19 | 2016-11-02 | Seattle Genetics Inc | Agentes de ligação a cd19 e seus usos |
| EP2398829A2 (en) | 2009-02-23 | 2011-12-28 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| WO2012067981A1 (en) | 2010-11-15 | 2012-05-24 | Medimmune, Llc | Combination therapy for b cell lymphomas |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| KR102117202B1 (ko) * | 2011-08-16 | 2020-06-01 | 모르포시스 아게 | 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법 |
| MX354479B (es) | 2011-08-16 | 2018-03-07 | Morphosys Ag | Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno. |
| EP2791165A4 (en) * | 2011-12-12 | 2015-08-05 | Pikamab Inc | PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY |
| CA2935748A1 (en) * | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| EP3157553A4 (en) * | 2014-06-16 | 2018-02-28 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| US10969391B2 (en) * | 2014-07-11 | 2021-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing hematological cancers |
-
2017
- 2017-05-30 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 HR HRP20240670TT patent/HRP20240670T1/hr unknown
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 PL PL21170716.1T patent/PL3916392T3/pl unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 SM SM20210291T patent/SMT202100291T1/it unknown
- 2017-05-30 ES ES21170716T patent/ES2981046T3/es active Active
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 SM SM20240204T patent/SMT202400204T1/it unknown
- 2017-05-30 SI SI201731527T patent/SI3916392T1/sl unknown
- 2017-05-30 MD MDE20220770T patent/MD3916392T2/ro unknown
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/en active Active
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active Active
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/en active Active
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 MX MX2018014702A patent/MX388502B/es unknown
- 2017-05-30 CN CN202211271570.5A patent/CN115932265A/zh active Pending
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 HU HUE21170716A patent/HUE067450T2/hu unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/en not_active Ceased
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 BR BR112018074603-7A patent/BR112018074603A2/pt active Search and Examination
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-01-15 ZA ZA2021/00296A patent/ZA202100296B/en unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US20220283166A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519770A5 (OSRAM) | ||
| Withers et al. | Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells | |
| JP2023093495A5 (OSRAM) | ||
| RU2017143166A (ru) | Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение | |
| Gianni et al. | Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) | |
| JP2022119854A5 (OSRAM) | ||
| FI3916392T3 (fi) | Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla | |
| JP2013542194A5 (OSRAM) | ||
| JP2018512170A5 (OSRAM) | ||
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| RU2014103490A (ru) | Комбинированная терапия с помощью антитела к cd19 и аналога пурина | |
| RU2019113370A (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
| RU2018107929A (ru) | Комбинации и их использование | |
| JP2021500916A5 (OSRAM) | ||
| JP2012519707A5 (OSRAM) | ||
| JP2019517485A5 (OSRAM) | ||
| RU2014103492A (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| Verschoor et al. | MicroRNA-155 is required for clearance of Streptococcus pneumoniae from the nasopharynx | |
| JP2017503481A5 (OSRAM) | ||
| JP2020523384A5 (OSRAM) | ||
| van Hooij et al. | BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease | |
| CN114773477B (zh) | 抗b7-h3抗体及其用途 | |
| MX2020007543A (es) | Metodos para administrar inmunoterapia de receptor de antigeno quimerico en combinacion con agonista 4-1bb. | |
| JP2020530002A5 (OSRAM) | ||
| JP2020500161A5 (OSRAM) |